Pacira BioSciences Inc
(FRA:82P)
€
21.6
+0.20 (+0.93%)
Market Cap: 865.47 Mil
Enterprise Value: 1.01 Bil
PE Ratio: 71.49
PB Ratio: 1.50
GF Score: 69/100 
Q2 2026 Pacira Biosciences Inc Earnings Call Transcript
Aug 04, 2026 / 08:30PM GMT
Release Date Price:
€23.4
(+3.54%)
Key Points
Positve
- Pacira BioSciences Inc (PCRX) delivered solid Q2 2026 financial results with total revenues of $192.4 million, a 6% increase year-over-year, and adjusted EBITDA of approximately $48.7 million.
- The company achieved a significant commercial milestone with UnitedHealthcare providing separate reimbursement for EXPAREL outside the surgical bundle, expanding access to over 150 million covered lives and potentially driving future adoption.
- Pacira BioSciences Inc (PCRX) successfully completed the divestiture of iovera to Zimmer Biomet, receiving $70 million upfront with potential for an additional $70 million in milestones, sharpening its focus as an innovation-driven biopharmaceutical company.
- The pipeline is advancing with multiple catalysts expected by year-end, including top-line data from the Phase 3 ZILRETTA shoulder OA study, the iovera spasticity registrational study, and Part A of the PCRX-201 Phase 2 ASCENT study.
- The company established a scalable, commercially viable U.S.-based manufacturing process for PCRX-201, a key step toward potential commercialization, and received acceptance of a Phase 1 manuscript for publication in the Annals of the Rheumatic Diseases.
- Pacira BioSciences Inc (PCRX) reported strong growth in its non-EXPAREL products, with ZILRETTA sales up 4% and iovera sales up 21% in Q2, driven by commercial investments and partnerships.
- The company maintains a strong balance sheet with $251 million in cash and investments, further enhanced by the $70 million upfront from the Zimmer transaction, positioning it well to fund its 5x30 growth strategy.
- Pacira BioSciences Inc (PCRX) is expanding its partnership network, including LG Chem's regulatory filing for EXPAREL in South Korea, which is expected to generate revenue starting in 2027.
- The company's focus on outpatient settings and macro-resilient procedures is yielding results, with EXPAREL volumes outpacing the broader market in ASCs and hospital outpatient departments.
- Pacira BioSciences Inc (PCRX) received a decisive shareholder vote supporting its 5x30 strategy and director nominees, indicating strong investor confidence in its direction.
Negative
- Pacira BioSciences Inc (PCRX) experienced a slowdown in elective soft tissue procedures, particularly in the hospital inpatient setting, due to macroeconomic pressures, which impacted EXPAREL volume growth to 4% in Q2.
- The company's total revenue guidance for 2026 was reduced to $735-$760 million from $745-$770 million, reflecting the impact of the iovera divestiture and ongoing macro headwinds.
- EXPAREL net sales growth of 3% was partially offset by a shift in vial mix and discounting from the third GPO, which went live mid-2025, pressuring revenue growth relative to volume.
- Non-GAAP SG&A expenses increased to $81.3 million in Q2, driven by non-recurring costs related to the contested election of directors at the 2026 Annual Meeting, which could weigh on profitability.
- The company faces uncertainty regarding the renewal of the NOPAIN Act, which is set to expire at the end of 2027, with potential legislative and regulatory hurdles that could impact future CMS reimbursement for EXPAREL.
- Pacira BioSciences Inc (PCRX) expects gross margins to be slightly below the full-year range in Q4 due to higher-cost inventory sales and shutdown-related costs, indicating potential margin pressure.
- The company's ZILRETTA guidance assumes the remainder of 2026 will be largely in line with 2025, suggesting limited near-term growth expectations despite recent quarterly performance.
- The iovera divestiture reduces the company's revenue base, and the $70 million upfront payment, while beneficial, may not fully offset the loss of future iovera sales and associated growth potential.
- The company's reliance on partnerships for ex-U.S. expansion, such as LG Chem, introduces execution risks and delays, with EXPAREL revenue from South Korea not expected until 2027.
- Pacira BioSciences Inc (PCRX) faces ongoing macroeconomic headwinds that could continue to impact elective procedures, and the company did not provide specific guidance on whether a recovery is needed to meet its second-half EXPAREL targets.
Operator
Thank you for standing by. Welcome to Pacira BioSciences' second quarter 2026 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Susan Mesco, Head of Investor Relations. Please go ahead.
Susan Mesco
Pacira Biosciences Inc - Investor Relations
Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our second quarter of 2026 financial results. Joining me are Frank Lee, Chief Executive Officer, Brendan Teehan, Chief Commercial Officer, and Shawn Cross, Chief Financial Officer. Kristen Williams, Chief Administrative Officer and Secretary, Anthony Molloy, Chief Legal Officer, and Jonathan Slonin, Chief Medical Officer, are also here for today's question and answer session.
Before we begin, let me remind you that this call will include forward-looking statements subject to the safe harbor provisions of federal securities laws. These statements represent our judgment as of today and may involve
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers